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A B S T R A C T
Objectives: The objective of this analysis was to estimate costs for lung cancer care and
evaluate trends in the share of treatment costs that are the responsibility of Medicare
beneficiaries.
Methods: The Surveillance, Epidemiology, and End Results (SEER)-Medicare data from
1991–2003 for 60,231 patients with lung cancer were used to estimate monthly and patient-
liability costs for clinical phases of lung cancer (prediagnosis, staging, initial, continuing,
and terminal), stratified by treatment, stage, and non-small- versus small-cell lung cancer.
Lung cancer-attributable costs were estimated by subtracting each patient’s own prediag-
nosis costs. Costs were estimated as the sum of Medicare reimbursements (payments from
Medicare to the service provider), co-insurance reimbursements, and patient-liability costs
(deductibles and “co-payments” that are the patient’s responsibility). Costs and patient-
liability costs were fit with regressionmodels to compare trends by calendar year, adjusting
for age at diagnosis.
Results: Themonthly treatment costs for a 72-year-old patient, diagnosedwith lung cancer
in 2000, in the first 6 months ranged from $2687 (no active treatment) to $9360 (chemo-
radiotherapy); costs varied by stage at diagnosis and histologic type. Patient liability repre-
sented up to 21.6% of care costs and increased over the period 1992–2003 for most stage and
treatment categories, evenwhen care costs decreased or remained unchanged. The greatest
monthly patient liability was incurred by chemo-radiotherapy patients, which ranged from
$1617 to $2004 per month across cancer stages.
Conclusions: Costs for lung cancer care are substantial, and Medicare is paying a smaller
proportion of the total cost over time.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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42 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 – 5 2ntroduction
ccurate estimates of costs are necessary for cost-effective-
ess analyses of cancer control interventions, such as mass
creening programs or chemoprevention. Detailed estimates
f costs are required to project future costs in the event that an
ntervention or screening program causes a change in inci-
ence, case mix, or treatment patterns. Cost analyses are also
ecessary to evaluate the societal benefit from investments in
herapies [1].
Medicare beneficiaries who are diagnosed with cancer
an face substantial financial burdens. Out-of-pocket
pending exceeded 25% of annual income for low-income
eneficiaries with cancer in 1995 [2], and increased among
ll beneficiaries between 1997 and 2003 [3,4]. Correlations be-
ween increases in out-of-pocket costs and changes in treat-
ent patterns could indicate disparities in care and should be
ssessed.
Lung cancer is the most common cancer diagnosis in the
nited States; there were 215,000 new cases in 2008 [5]. Lung
ancer accounts for 20% of Medicare’s total expenditures for
ancer treatments [6]. We sought to estimate costs for all
hases of lung cancer (pre-diagnosis, staging, initial treat-
ent, continuing care, and terminal care) for use in a policy
odel of lung cancer that simulates patient lifetimes in
onthly increments. Cost estimates in the literature were in-
omplete for our purposes for several reasons: categories of
hases of care or treatment were collapsed or not reported;
osts were those toMedicare or other payers only (i.e., exclud-
ng costs paid by beneficiaries); samples were small or non-
eneralizable (e.g., HMOs); or covered periods before 1991
6–11]. We estimated monthly (as opposed to annual) costs to
e consistent with the policy model. Also, a patient with lung
ancer has amedian survival of less than 1 year and 12-month
hases of care could obscure theU-shaped cost pattern typical
n cancer [1,11,12]. Additionally, Yabroff et al. [13] reviewed 60
nalyses of cancer treatment costs and found that 50% of
hem used “unclear” methods.
Using the Surveillance, Epidemiology, and End Results
SEER)-Medicare database for years 1991 through 2003, we
stimated direct lung cancer care costs for individuals diag-
osed with lung cancer between 1992 and 2002. We strati-
ed costs by stage at diagnosis, histologic type (nonsmall
ell vs. small cell), treatment, and phase of care (prediagno-
is, staging, initial, continuing, and terminal). Treatment
osts include Medicare reimbursements, co-insurance re-
mbursements, and patient-liability costs (deductibles and
co-payments” that are the patient’s responsibility but may
e paid in part or whole by employer-sponsored supple-
ental coverage, Medicaid dual-eligibility, or through pa-
ient-purchased Medigap coverage), which are not typically
ncluded in analyses of Medicare costs. Using linear regres-
ion analysis, we tested the hypotheses that costs were in-
uenced by the age of the patient, that costs changed over
ime, and that the effect of age on cost may have changed
ver time. In addition, we compared the trends we observed
or total and lung cancer–attributable costs to the trends for
he patient liability. uethods
EER-Medicare data and inclusion/exclusion criteria
EER-Medicare data consist of cancer registry files from SEER
inked to claims data from Medicare, which is the primary
ealth insurer for 97%of theUSpopulationmore than 65 years
ld [14,15]. During the entire time frame used in this longitu-
inal analysis (1991 through 2003, inclusive), the SEER pro-
ram collected data from 13 regions—including Connecticut,
awaii, Iowa, New Mexico, Utah, Atlanta, Detroit (Michigan),
an Francisco-Oakland (California), Seattle-Puget Sound
Washington), Los Angeles (California), San Jose-Monterey
California), rural Georgia, and the Alaska Native Tumor Reg-
stry—that represented approximately 14% of the total US
opulation. In 2000, SEER expanded to 17 regions, with the
ddition of Greater California, Kentucky, Louisiana, and New
ersey, in total representing 26% of the US population [16]. In
his analysis, we used all the data available for each year. A
etailed description of the SEER-Medicare linked database, in-
luding its use in compliance with HIPAA regulations, is avail-
ble at: http://healthservices.cancer.gov/seermedicare/.
We includedMedicare beneficiariesmore than 65 years old
ho were diagnosed with an American Joint Committee on
ancer (AJCC) stages I–IV lung cancer between May 1, 1992,
nd December 31, 2002 and had no previous or subsequent
ancer diagnosis. We included individuals continuously en-
olled in both Part A and Part B Medicare coverage from 15
onths prior to cancer diagnosis through death or the end of
he study period (December 31, 2003).We excluded individuals
nrolled in managed care at any time during the study period
ecause health maintenance organizations do not submit de-
ailed claims to Medicare. Patients who received Medicare
enefits because of disability or end-stage renal disease were
lso excluded. Individuals with no claims for an entire phase
f cancer care (defined below) were excluded from the analy-
is of that phase because we assumed they were receiving a
inimum amount of treatment, supportive care, or were
onitored by another component of the health system, such
s Veterans Affairs. Finally, patients were excluded if the
onth of diagnosis was unknown, if diagnosis was made at
utopsy, or if the date of death recorded in the Medicare da-
abase differed from the date of death recorded in the SEER
atabase by more than 3 months.
efining treatments
reatment groups were defined based on lung cancer treat-
ents received from up to 2 months prior to diagnosis and
ncluding 6 months post-diagnosis for individuals diagnosed
n AJCC stages I through III. For individuals diagnosed with
tage IV cancer, treatment groupwas assigned based on treat-
ents ever received. Costs are reported for treatment groups
ith 10% of patients in the type/stage category, except for
upportive care only (reported for all categories).
We defined resection as local surgery, wedge resection,
neumonectomy, or lobectomy. Procedures were identified
sing International Classification of Diseases–9th Revision–
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43V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 – 5 2linical Modification (ICD-9-CM) procedure and Current Pro-
edure Terminology (CPT) codes: local surgery (ICD-9-CM
2.09 or 32.1x; CPT 32520); wedge resection (ICD-9-CM 32.29 or
2.3x; CPT 32500); pneumonectomy (ICD-9-CM 32.5x or 32.6x;
PT 32440, 32442, or 32445); and lobectomy (ICD-9-CM 32.4x;
PT 32480, 32482, 32484, or 32486). We additionally included
CD-9-CM codes 32.9x, 40.11, or 40.19 and CPT codes 32999 or
8786.
We defined a patient as having received any chemotherapy
f there was a hospice, home health, inpatient, outpatient,
hysician, or durable medical equipment claimwith any code
or chemotherapy administration (ICD-9-CM procedure 99.25,
CD-9-CM diagnosis V58.1, CPT 96400-96549, Healthcare Com-
on Procedure Coding System (HCPCS) codes C1166, C1167,
1178, C9110, C9205, C9207, C9213-C9216, C9411, C9414-
9419, C9420-C9438, G0355, G0356, G0359-G0362, J7150, J8500-
8799, J8999-J9999, Q0083-Q0085, S9325-S9329, S9330-S9379,
9494-S9497 or revenue center codes 0331, 0332, 0335) [14].
We identified patients who received radiation therapy us-
ng Medicare claims for radiation treatment planning or ad-
inistration in any of the Medicare claims files (same files
sed for chemotherapy) (ICD-9-CM procedures 92.20-92.29;
CD-9-CM diagnosis V58.0, CPT 77000-77999, 79000-79999,
CPCS S8049, or revenue center codes 0330, 0333, 0339).
efining phases of care
osts were assigned to phases of care (Fig. 1) that were clini-
ally identifiable. Due to the short median survival of patients
ith lung cancer, a 12-month initial or terminal phase used in
ost assessments of longer-surviving patientswere not appro-
riate because the entire length of time of lung cancer treat-
ent may be considered “terminal phase” care [6,9,17–20].
hen shorter phases of care are used (e.g., a 6-month initial
ig. 1 – (A) Phases of care for patients undergoing non-surgi
esection. The median time between diagnosis and surgery
iagnosis and surgery was more than 6 weeks.hase), the “U-shape” common to the cost of caring for pa-
ients with cancer [1,6,21,22] can be observed in patients with
ung cancer [10,23].
For all patients, the prediagnosis phase was defined as the
2-month period beginning 15 months prior to diagnosis
where diagnosis was defined as pathological evidence of lung
ancer). The 3 months immediately prior to diagnosis were
xcluded to avoid including the costs of treating symptoms of
n undiagnosed cancer.
For patients not undergoing resection, the month of diag-
osis was defined as the staging phase. A month-long staging
hase was based on typical clinical practice at our institution.
reatment was divided into three phases: initial (6-month pe-
iod beginning the month after diagnosis and excluding the
onth before death); continuing (subsequent post-diagnosis
eriod and excluding the month of death); and terminal (the
onth in which death occurred).
For patients undergoing resection,we defined themonth of
urgery as the 30 days that began on the date of surgery. Be-
ause isolating the cost of surgery from that of postoperative
are is necessary to assign costs accurately in simulation
odelswith stochasticmortality events, we defined the initial
hase for resection as the 6-month period beginning 30 days
ost-resection (Fig. 1). The monthly staging phase cost as de-
ned for other treatments was impossible to calculate for resec-
ion because of heterogeneity in the time required for preopera-
ive assessment. More than half (53%) of surgical patients
eceived surgerywithin amonthof diagnosis,making amonthly
tagingphasecost impossible todefine. For the remaining47%of
atients whose surgery occurred in amonth after diagnosis, we
xcluded costs occurring between the month of diagnosis and
he date of admission.
The terminal phase was defined as the month of death to
ermit distinction between phases of care even in patients
eatments. (B) Phases of care for patients undergoing
18 days; however, for 20% of patients the time betweencal tr
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44 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 – 5 2ith limited survival. Because we had organized the data into
alendar months starting from month of diagnosis, we used
n actuarial approach (see Supplemental Methods) to calcu-
ate the expected cost for the last month of life.
efining lung cancer types and causes of death
atients were grouped into small-cell lung cancers (SCLC) (In-
ernational Classification of Diseases Oncology, 3rd edition
ICD-O-3] codes 8041, 8042, 8043, 8044) versus non-small-cell
ung cancers (NSCLC; ICD-O-3 codes 8010, 8012, 8070, 8071,
072, 8140, 8481, 8560), because treatment varies by histologic
ype. SCLC was staged as either limited (AJCC stages I–III) or
xtensive stage (AJCC stage IV).
Individuals whose death was observed on or before De-
ember 31, 2003, were classified by cause of death (lung cancer
excluding operative deaths], ICD-9-CM diagnosis 162.xx; car-
iac-related causes, ICD-9-CM 390.xx-398.xx, 402.xx, and
04.xx-429.xx; and all other causes) according to death certif-
cate information in SEER. Death within 30 days of surgical
esection for lung cancer was defined as an operative death.
efining costs
ostswere estimated as the sumofMedicare reimbursements
payments from Medicare to the service provider), co-insur-
nce reimbursements (payments from a co-insurer to the ser-
ice provider [in cases in which Medicare is the secondary in-
urer because the patient is still primarily insured throughhis or
er employer]), and patient-liability costs (deductibles and “co-
ays” that are thepatient’s responsibility butmaybepaid inpart
r whole by employer-sponsored supplemental coverage, Med-
caiddual-eligibility, or throughpatient-purchasedMedigapcov-
rage). The portion of the patient’s liability that the patient pays
ut-of-pocket at the timeof service (vs. theportion that ispaidby
edigap coverage purchased by the patient to reduce point-of-
ervice expenses) cannot be determined in the SEER-Medicare
les. Variables used in the analysis are presented in the Appen-
ix 1 SupplementalMethods found at: 10.1016/j.jval.2010.10.006.
The cost of operative death for this study was equal to the
um of payments (from Medicare, other payers, and the pa-
ient) for patients who died within 30 days of resection and
ncluded the cost of resection.
Cancer-attributable costs are typically estimated using a
ase-control approach, drawing controls from the random 5%
ample of Medicare enrollees residing in SEER areas [1,24]. We
ave not taken this approach because patients with lung can-
er may differ from the general population with respect to
ealth behaviors, particularly related to smoking [25]. Thus, to
alculate cancer-attributable costs in this study, each patient
erved as his or her own control: we subtracted each patient’s
ean monthly prediagnosis cost from the monthly costs for
he initial and continuing phases of care.
Consistent with other analyses using this data set [6,17]
nd following the recommendations by Brown et al. [1] , pay-
ents were converted to constant 2006 US dollars by adjust-
ng Part A claims using the Centers for Medicare andMedicaid
ervices (CMS) Prospective Payment System Hospital Price in- (ex and Part B claims using the Medicare Economic Index
26,27]. All costs are presented in constant (inflation adjusted)
006USdollars and, thus, if costs are observed to increase over
ime, this indicates that costs are increasing at a faster rate
han are overall Medicare payments per patient.
tatistical analysis
o compare trends in treatment costs with trends in patient-
iability costs over the time period 1992–2003 while adjusting
or changes in patient ages, linear and exponential models for
ach stage and treatment category were fit with treatment
ost and (separately) patient-liability costs as the dependent
ariable and coefficients for year of diagnosis, age at diagno-
is, and an interaction term between age and year. Using sig-
ificant (  0.05) coefficients from linear models, costs were
tandardized to correspond to a patient diagnosed at age 72 in
000; 72 was the median age of diagnosis. When neither age
or year of diagnosis (or the interaction) was significant, costs
or a patient diagnosed at age 72 in 2000 is equivalent to the
verage cost of the entire cohort. Signs of significant terms
rom the linear model with only significant terms are report-
d; coefficients are available in Supplemental Results. Expo-
ential models had similar terms but in all cases explained
ess variability than linear models and are not reported. All
ata were analyzed using SAS 9.1.3 (Cary, NC, USA).
esults
ample characteristics
total of 60,231 lung cancer patients were included in the sam-
le (Table 1). Most (58.9%) patients were diagnosed between 70
nd80yearsof age. Thirteenpercent (n7939) of patients lacked
ither histologic type or stage-at-diagnosis information and
ere excluded from stratified analyses of treatment category
nd costs. Most (83%) patients included in the initial phasewere
iagnosedwith NSCLC, with 34.9% of NSCLC patients diagnosed
ith Stage I or II disease. A substantial portion (16%, n9617) of
ll patients diedwithin 2months of diagnosis andwere included
nly in the terminal phase.Deathoccurredwithin thewindowof
nalysis for 45,777 patients (76% of total), with 81.2% of deaths
ttributed to lung cancer and 4.4%of deaths attributed to cardio-
ascular causes. Few patients (1.2% of total) died because of op-
rative causes.
osts of prediagnosis (baseline) and terminal phase care costs
patient diagnosed with lung cancer at 72 years of age in 2000
ould have incurred an average of $645/month in health care
xpenditures prior to diagnosis, $107 (16.6%) of which were the
atient’s responsibility (Table 2). Prediagnosis health care costs
or a 72-year-old patient increased by 22% over 10 years, whereas
he patient-liability portion increased 119% over the same period.
The cost of care in the last month of life for a 72-year-old
ndividual diagnosed in the year 2000 was $14,987 for death
rom lung cancer and $19,173 for death from cardiac causes
Table 2). Over 10 years, the costs of death from lung cancer
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45V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 – 5 2nd cardiac causes (for patientswith lung cancer) increased by
.6% and 23.3%, respectively. For both causes of death, in-
reasing age at diagnosiswas associatedwith a decreased cost
f the terminal phase: a reduction of $160 per each additional
ear of age for lung cancer death and a reduction of $213 per
ach additional year of age for cardiac death. Neither age-at-
iagnosis nor year-of-diagnosis predicted the cost of opera-
ive death (mean $38,088; standard error [SE], $1150).
osts of cancer care
otal costs and patient-share costs for a 72-year-old patient
n the year 2000 are provided for the staging phase (Table 3),
he initial phase (Table 4), and the continuing care phase
Table 5); also see Figure 2. Net cancer-attributable costs are
rovided for the initial phase. Significant (P  0.05) terms
rom linear regressions with age, year of diagnosis, and an
nteraction term (age*year) are listed with a sign to indicate
ositive () or negative () correlations (see Supplemental
Table 1 – Description of study subjects.
Number Percent
Numbers of patients per phase*
Prediagnosis 60,231
Diagnosis and staging 42,675
Initial 37,886
Year of diagnosis†
1992 1883 5.0
1993 2857 7.5
1994 2921 7.7
1995 2948 7.8
1996 2921 7.7
1997 2784 7.3
1998 2851 7.5
1999 2826 7.5
2000 5854 15.5
2001 5051 13.3
2002 4990 13.2
Age at diagnosis†
65–69 years 7137 18.8
70–74 years 12,235 32.3
75–79 years 10,096 26.6
80 years 8418 22.2
Histologic type and stage at diagnosis†
NSCLC, stages I and II 10,987 29.0
NSCLC, stage III 11,405 30.1
NSCLC, stage IV 9117 24.1
SCLC, limited stage 3224 8.5
SCLC, extensive stage 3153 8.3
Continuing 18,933
Terminal‡ 45,777
Lung cancer deaths 37,170 81.2
Cardiac deaths 2030 4.4
Operative deaths 565 1.2
All other cause deaths 6012 13.1
NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.
* See Methods and Figure 1 for definitions of phases of care.
† Limited to the 37,886 patients included in the initial phase analysis.
‡ ICD-9 codes 162 (lung cancer); 390–8,402,404–429 (cardiac).ata for coefficients).taging phase
orpatientswhoreceivedno treatment, thecostofhealthcare in
he month of lung cancer diagnosis ranged from $10,631 to
13,404. After subtracting average prediagnosis costs of $645 per
onth, we can estimate that diagnosis and staging cost $10,000
o $13,000 in standard clinical practice during the study period.
he patient-liability in the month of lung cancer diagnosis was
imilar (range, $1261–$1534) across patients who received no
reatment, regardless of histologic type or stage of diagnosis.
Table 2 – Average monthly health care costs during the
prediagnosis and terminal phases.
Cost, age 1992 2000 2003 10-year*
% change
Total cost, prediagnosis
phase
65 455.89 553.62 590.27 26.8
70 520.80 618.54 655.19 23.5
72 546.77 644.50 681.15 22.3
75 585.72 683.45 720.10 20.9
80 650.64 748.37 785.02 18.8
Patient-liability,
prediagnosis phase
65 46.40 98.71 118.33 140.9
70 52.57 104.88 124.49 124.4
72 55.04 107.34 126.96 118.8
75 58.74 111.04 130.66 111.3
80 64.90 117.21 136.83 100.7
Total cost, lung cancer
death
65 15,151 16,110 16,470 7.9
70 14,348 15,308 15,667 8.4
72 14,027 14,987 15,346 8.5
75 13,546 14,505 14,865 8.9
80 12,744 13,703 14,063 9.4
Total cost, cardiac
death
65 17,652 20,665 21,794 21.3
70 16,587 19,599 20,729 22.7
72 16,160 19,173 20,302 23.3
75 15,521 18,533 19,663 24.3
80 14,455 17,467 18,597 26.0
Notes: Costs are estimated for a 72-year-old patient in the year 2000
using the linear regression of the form: Monthly Cost Constant
Age *(Age in years) Year *(Calendar Year – 1992) Age*Year *(Age
in years) *(Calendar Year – 1992). Terms were included in the final
model using a threshold of   0.05. Age and calendar year of diag-
nosis were significant (P  0.0001) predictors of both prediagnosis
total costs and patient liability; the interaction termwas not signif-
icant and so was excluded from the final models. Regression coef-
ficients are presented in Supplementary Table 2A. Total cost is the
sum of average monthly costs from all sources regardless of payer
[Total CostCancer - Attributable CostsNon-CancerAttributable
Costs Patient LiabilityMedicare or other primary insurer liabil-
ity]. Patient liability is defined as the amount of total health care ex-
penses that are the responsibility of the patient for both cancer-attrib-
utable and non-cancer health care, such as deductibles and “co-
payments.” Patient liabilitymay be paid in part orwhole by employer-
sponsored supplemental coverage, Medicaid dual-eligibility, or
through patient-purchased Medigap coverage.
* Calculated using calculated values for 1992 and 2002.
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46 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 – 5 2For patients with NSCLCwho received radiotherapy and/or
hemotherapy, staging phase costs ranged from $12,411 to
16,619 and decreased with age, except for stage III chemora-
iotherapy. Staging phase costs for treating patients with
CLC ranged from $16,105 to $17,321. The interaction term of
ge at diagnosis and year of diagnosis was never significant,
ndicating there was no evidence for a change in the effect of
ge on the costs of treatment over time. Higher staging phase
osts for patients who subsequently received treatment may
e explained by differences in the patients not captured in this
nalysis (baseline health status), less aggressive staging regi-
ens for patients who have stated their preference not to
eceive active treatment, or the inclusion of some initial treat-
ent costs in the staging phase.
The share of staging phase costs thatwas the responsibility
f beneficiaries increased significantly over the time frame of
ur analysis for all treatments, histologic types, and stages,
ven when overall staging phase costs remained stable or de-
lined. Among patients who subsequently received active
reatment, the patient-liability was 13.3% to 18.7% of the over-
Table 3 – Average monthly costs (total and patient liability
and treatment strategy.
Total cost
Age-, year-standardized
(72 years in 2000)
NSCLC
Stages I and II*
No treatment 10,631
Radiotherapy 12,411
Stage III
No treatment 13,404
Radiotherapy 14,439
Chemotherapy & radiotherapy 14,133
Stage IV
No treatment 11,908
Radiotherapy 16,619
Chemotherapy 14,062
Chemotherapy & radiotherapy 16,599
SCLC
Limited Stage
No treatment 11,279
Chemotherapy 16,467
Chemotherapy & radiotherapy 16,105
Extensive Stage
No treatment 11,158
Chemotherapy 16,309
Chemotherapy & radiotherapy 17,321
Notes: Treatment categories with less than 10% of patients are not s
received other treatments. Costs are estimated for a 72-year-old pa
Cost Constant Age *(Age in years) Year *(Calendar Year – 1992)
the finalmodel using a threshold of  0.05. Regression coefficients a
we present the mean over all patients. Total cost is the sum of av
Cancer-Attributable Costs Non-Cancer Attributable Costs Patient
defined as the amount of total health care expenses that are the respo
care such as deductibles and “co-payments.” Patient liability may b
Medicaid dual-eligibility, or through patient-purchased Medigap cove
NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.
* We did not calculate a staging phase for resection surgery because
from diagnosis until surgery was 18 days, see Figure 1B).ll staging phase costs. tnitial phase
n all cases where age at diagnosis was a significant predictor of
nitial phase cost, increasingageat diagnosis resulted ina reduc-
ion in cost. The interaction term of age at diagnosis and year of
iagnosiswasnever significant indicating therewasnoevidence
or a change in the effect of age on the costs of care over time.
Except in one case (stage IVNSCLC), the initial phase costs for
atients who received no treatment were not significantly asso-
iated with patient age or year of diagnosis and were similar
crosshistologic typesandstagesofdiagnosis. Themonthly cost
f care for patients in the initial phase who received no active
reatment (supportive care only) ranged from $2687 to $3565,
nd the lung cancer-attributable portion ranged from $1779 to
2680. Monthly patient liability for a typical lung cancer patient
eceivingno active treatmentwas similar across histologic types
nd stages at diagnosis, ranging from $215 to $286 a month, an
ncrease of two- to threefold over the patient-liability portion of
ealth care costs prior to lung cancer diagnosis.
A 72-year-old patient in 2000 receiving an active course of
the staging phase by histologic type, stage at diagnosis,
Patient liability
Significant
terms
Age-, year-standardized
(72 years in 2000)
Significant
terms
1261 Year ()
e () 1887 Year ()
1444 Year ()
e () 2190 Year ()
ar () 2643 Age (), year ()
ar () 1534 Age (), year ()
e (), year () 2370 Age (), year ()
e () 2305 Age (), year ()
e () 2909 Age (), year ()
ar () 1398 Year ()
2365 Age (), year ()
e (), year () 2702 Age (), year ()
1479 Year ()
e () 2433 Age (), year ()
2312 Year ()
, see the Supplementary Results for the proportion of patients who
in the year 2000 using the linear regression of the form: Monthly
ge*Year *(Age in years)*(Calendar Year – 1992). Terms were included in
sented in Supplementary Table 3A.When no termswere significant,
monthly costs from all sources regardless of payer [Total Cost 
ilityMedicare or other primary insurer liability]. Patient-liability is
lity of the patient for both cancer-attributable and non-cancer health
d in part or whole by employer-sponsored supplemental coverage,
.
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47V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 – 5 2onth, with the highest amount being incurred by NSCLC
atients with stage III disease receiving chemoradiotherapy.
Patients receiving chemotherapy and chemoradiation had
ighcosts in the initial period:monthlycancer-attributable costs
or a 72-year-old patient diagnosed in 2000 ranged from $6760 to
8831 and inmost cases increased over time, but decreasedwith
ncreasing patient age. Radiotherapy costs decreased over time.
atients receiving chemotherapy and chemoradiation incurred
he greatest patient-liability, ranging from $1214 to $2004 per
onth (15%-22% of total health-care costs). Except for support-
ve care, the patient-liability amount increased over time even
hen overall costs did not. For example, no increase in costs
ere observed over time for treating stage III NSCLC patients
ith chemoradiotherapy, yet patients were responsible for an
dditionalmonthly liability of $96with each additional year of
Table 4 – Initial phase monthly costs (total, cancer attributa
and treatment.
Number (%) Total cost
Age-, year-
standardized
(72 years in 2000)
Significant
terms
NSCLC
Stages I and II 10,987
No treatment 1253 (11.4) 2687
Surgery* 5265 (47.9) 5255
Radiotherapy 2080 (18.9) 5671 Age ()
Stage III 11,405
No treatment 1723 (15.1) 3234
Radiotherapy 3014 (26.4) 5794 Age ()
Chemotherapy &
radiotherapy
2763 (24.2) 9257 Age ()
Stage IV 9117
No treatment 1269 (13.9) 3398 Age ()
Radiotherapy 2576 (13.1) 5391 Age ()
Chemotherapy 1192 (28.3) 7677 Age (), year (
Chemotherapy &
radiotherapy
3209 (35.2) 8927 Age (), year (
SCLC
Limited Stage 3224
No treatment 243 (7.5) 3565
Chemotherapy 713 (22.1) 8291 Age (), year (
Chemotherapy &
radiotherapy
1673 (51.9) 9360 Age ()
Extensive Stage 3153
No treatment 170 (5.4) 2878
Chemotherapy 777 (24.6) 7487
Chemotherapy &
radiotherapy
1824 (57.8) 8840 Year ()
Notes: Treatment categories with less than 10% of patients are not s
received other treatments. Patients who lived fewer than 2months co
to the initial phase. Costs are estimated for a 72-year-old in the year 20
*(Age in years)  Year *(Calendar Year – 1992)  Age*Year *(Age in yea
a threshold of  0.05. Regression coefficients are presented in Suppl
over all patients. Total cost is the sum of average monthly costs from
Non-Cancer Attributable Costs  Patient-Liability  Medicare or othe
individual patient’s monthly cost of health care incurred in excess of
the amount of total health care expenses that are the responsibility o
as deductibles and “co-payments.” Patient liability may be paid in
dual-eligibility, or through patient-purchased Medigap coverage.
NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.
* 6 months following surgery month, see Figure 1B.iagnosis. lonth of surgery
oth increasing age at diagnosis (P 0.0021) and earlier year of
iagnosis (P 0.0001) were significant predictors of increasing
otal cost (Table 4B at: 10.1016/j.jval.2010.10.006, for regression
oefficients). The average lung cancer patient (72 years old) diag-
osed in 2000 would have incurred approximately $26,235 in
ealth care expenditures in the month of surgery, including
1400 inpatient liability. Even though the total costofhealthcare
n themonth of surgery decreased by $282 each year (a decrease
f 10% over 10 years), patient-liability costs increased $59 with
ach additional year of diagnosis (a 63% increase over 10 years).
Neither overall health care costs ($5255/month) nor net can-
er-attributable costs ($4654/month, beginning 30days after sur-
ery)werepredictedbyageor year of diagnosis (Table 4). Patient-
and patient share) by histologic type, stage at diagnosis,
et cancer-attributable cost Patient liability
Age-, year-
tandardized
years in 2000)
Significant
terms
Age-, year-
standardized
(72 years in 2000)
Significant
terms
1779 286 Year ()
4654 215 Year ()
4323 Age (), year () 1148 Year ()
2327 275 Year ()
4855 Age (), year () 1158 Year ()
8752 Age () 2004 Age (), year ()
2557 Age () 264 Year ()
4857 Age () 899 Age (), year ()
7132 Age (), year () 1326 Age (), year ()
8466 Age (), year () 1698 Age (), year ()
2680 277
7533 Age (), year () 1229 Year ()
8831 Age () 1948 Age (), year ()
2182 215
6760 1214 Age (), year ()
8354 Age (), year () 1617 Year ()
, see the Supplementary Results for the proportion of patients who
uted amonth to the staging phase and to the terminal phase but not
ing the linear regression of the form:Monthly CostConstant Age
alendar Year – 1992). Terms were included in the final model using
tary Table 4A.When no termswere significant, we present themean
urces regardless of payer [Total Cost  Cancer-Attributable Costs 
mary insurer liability]. Net cancer-attributable cost is defined as the
erage pre-diagnosis cost of health care. Patient liability is defined as
atient for both cancer-attributable and non-cancer health care such
r whole by employer-sponsored supplemental coverage, Medicaidble,
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48 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 – 5 2y patients who received no treatment ($215/month), and in-
reased over time ($6 per additional year of diagnosis).
ontinuing phase
verall health care and lung cancer-attributable health care
osts during the continuing phasewere either not affected by or
ecreased with increasing age and increasing calendar year of
iagnosis. In one case, patients with stage IV NSCLC who re-
eived no treatment, the interaction term of age and year of di-
gnosis was a significant predictor of cost that indicated the ef-
ect of age on overall health care was not constant over time.
Table 5 – Continuing phase monthly costs (total, cancer-att
diagnosis, and treatment.
N (%) Total cost
Age-, year-
standardized
(72 years in
2000)
Significant
terms
NSCLC
Stages I and II 7521
No treatment 665 (8.8) 4498
Surgery 4335 (57.6) 2602 Year ()
Radiotherapy 1079 (14.3) 5403
Stage III 5364
No treatment 663 (12.4) 5139 Year ()
Radiotherapy 1176 (21.9) 6941
Chemotherapy &
radiotherapy
1302 (24.3) 8196 Year ()
Stage IV 2924
No treatment 334 (11.4) 5538 Age (), year ()
Age* year ()
Radiotherapy 598 (20.5) 8287 Age ()
Chemotherapy 411 (14.1) 10,026
Chemotherapy &
radiotherapy
1215 (41.6) 11,178 Age ()
SCLC
Limited stage 1732
No treatment 100 (5.8) 5975
Chemotherapy 336 (19.4) 9445
Chemotherapy &
radiotherapy
972 (56.1) 8807
Extensive stage 1392
No treatment 51 (3.7) 4850
Chemotherapy 285 (20.5) 10,660
Chemotherapy &
radiotherapy
914 (65.7) 12,344
Notes: Treatment categories with fewer than 10% of patients are not s
received other treatments. Patients who lived between 2 and 7month
between 1 and 6months to the initial phase, but nomonths to the cont
using the linear regression of the form: Monthly Cost  Constant 
years)*(Calendar Year – 1992). Terms were included in the final mod
Supplementary Table 5A.When no termswere significant, we presen
from all sources regardless of payer [Total Cost  Cancer-Attributable
other primary insurer liability]. Net cancer-attributable cost is defined
of the average prediagnosis cost of health care. Patient-liability is defi
of the patient for both cancer-attributable and non-cancer health car
part or whole by employer-sponsored supplemental coverage, Medic
NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.
* Continuing phase costs were for the 6 months following the monthimilar patterns of change in patient liability were observed in the tontinuing phase of lung cancer treatment as were observed in
ther periods of care (staging, initial phase, and surgery); the
mountof the liability increasedor remainedstableover timeeven
hen overall health care costswere stable or decreased over time.
iscussion
stimation of medical costs paid by insurers and patients is
ecessary to conduct cost-effectiveness analyses of lung can-
er control interventions from the societal perspective, in
hich all costs are included without regard for who accrues
table, patient-share) by histologic type, stage at
et cancer-attributable cost Patient-liability cost
ge-, year-
andardized
2 years in
2000)
Significant
terms
Age-, year-
standardized
(72 years in
2000)
Significant
terms
3721 414 Year ()
1996 Year () 341
4428 590 Age (), year ()
4313 Year () 422
6309 762 Age (), year ()
7758 Year () 1073 Age ()
4733 Age (), year (),
Age* year ()
451
7789 Age () 807 Year ()
9425 1465 Age ()
10,767 Age () 1609 Age (), year ()
5127 583
8834 1296
7922 Year () 1204
4507 380
9941 1541 Year ()
11,829 1900 Year ()
n, see the Supplementary Results for the proportion of patients who
tributed amonth to the staging phase and to the terminal phase and
g phase. Costs are estimated for a 72-year-old patient in the year 2000
*(Age in years)  Year *(Calendar Year – 1992)  Age*Year *(Age in
ng a threshold of   0.05. Regression coefficients are presented in
ean overall patients. Total cost is the sum of averagemonthly costs
s  Non-Cancer Attributable Costs  Patient-Liability Medicare or
e individual patient’s monthly cost of health care incurred in excess
s the amount of total health care expenses that are the responsibility
h as deductibles and “co-payments”. Patient-liability may be paid in
ual-eligibility, or through patient-purchased Medigap coverage.
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49V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 – 5 2nnual cancer-related costs to Medicare [7,29], our cost esti-
ates contribute detail to the literature about financial re-
ponsibilities faced by Medicare beneficiaries treated for lung
ancer, themost common cause of cancer death in the United
tates. Our estimates provide monthly health care costs
stratified by patient age, phase of care, histologic type, stage
t diagnosis, and calendar year of diagnosis).
We found that the amount and the proportion of overall
osts that are the responsibility of patients to pay or to insure
gainst (such as by purchasing Medigap coverage) increased
ignificantly from 1992 to 2003, even for treatments with sta-
le or decreasing overall costs, thus confirming earlier studies
3,4] that suggest an increase in cost-shifting to beneficiaries.
mong categories in which we observed an increase in the
verall cost of health care, the increase in the patient liability
epresented 37.9% to 95.7% of the total increase in overall
ig. 2 – Average monthly costs (total and patient-liability) fo
egression stratified by histologic type, stage at diagnosis, a
NSCLC) and (B) small-cell lung cancer (SCLC). Chemo, chemo
adiotherapy.osts. The same pattern of an increasing patient liability was epparent for most phases of care and most treatment catego-
ies. Monthly initial phase costs thatwere the responsibility of
72-year-old patient treated in 2000 with combined chemo-
herapy and radiotherapy were estimated between $1617 and
2004, representing 72% to 89% of the median monthly per-
apita income for Americans over 65 years of age ($2258, all in
006$) [30]. Note, however, that patient-liability costs in tradi-
ional Medicare are not necessarily paid out-of-pocket by the
atient. During the period of this analysis, approximately one-
hird of beneficiaries had employer-sponsored supplemental
overage that reduced point-of-service obligations, approxi-
ately 30% had Medigap coverage, and 20% were dually eligi-
le for Medicaid [31]. Medigap is the only supplemental cover-
ge available to all beneficiaries. In 1999, the average annual
ost of a Medigap policy was $1311 per year [32]. Consistent
ithwhatwould be expected as the patient liability increases,
-year-old patient in the year 2000 as estimated by linear
eatment strategy for (A) non-small-cell lung cancer
apy; ChemoRT, chemotherapy and radiotherapy; RT,r a 72
nd tr
thermployer-sponsored supplemental coverage is decreasing in
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50 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 – 5 2requency and in generosity of benefits; the cost of Medigap
overage is increasing [31,32]. Our findings echo questions
aised in prior studies about the sustainable affordability of
ealth care for Medicare beneficiaries as the proportion of
osts paid by Medicare decreases over time [4,33,34].
Whether the patient liability is paid by the patient as a
oint-of-service expense or paid through supplemental cov-
rage the patient previously purchased to insure against
oint-of-service expenses will affect decisions at the point of
ervice and may impact total cost and patient-liability differ-
ntly depending on the mix of services the patient chooses
35,36]. In the SEER-Medicare data set, we cannot distinguish
etween payments made directly by patients and payments
aid on their behalf by supplemental insurance. Thus, these
ata do not allow us to determine whether patients chose less
ffective treatments with lower out-of-pocket costs. Lack of
atient and physician familiarity with the cost burdens that
atients face with each treatment option limit the potential
or patients to make decisions based on cost. However, if
ewer patients have supplemental coverage in the future and
s patients becomemore aware of their payment responsibil-
ties, the repercussions of high out-of-pocket costs could con-
eivably cause a shift in treatment choice, leading to underuse
f recommended services in favor of less effective but more
ffordable services [37–39]. Furthermore, high medical costs
an reduce access to health care for other householdmembers
2]. Recommended therapies have previously been shown to
e less common in under-represented minority groups com-
ared to whites [40–44]. Increases in out-of-pocket burdens
n low-income patients may result in increased demand for
edicaid services or reduced use of health care services by the
conomically disadvantaged who are more often members of
nder-represented minority groups [30], magnifying dispari-
ies [45].
Only patients diagnosed with stages I/II NSCLC followed
he classic pattern of higher costs in the initial phase followed
y lower costs in the continuing care phase. In part, this may
e explained by the short life expectancy associated with lung
ancer and our definition of the terminal phase as only the last
onth of life. The average number of months in the continu-
ng phase was short and many patients were principally in
reterminal phases that may have included expensive pain
ontrol treatments (e.g., fentanyl) or extended palliative care
n hospice. We observed a general trend of increasing costs in
he terminal phase of care which is consistent with trends of
ncreasing use of aggressive care (emergency room visits, in-
ensive care unit admissions, systemic therapy) near the end
f life in lung cancer and other diseases [8,46,47]. Consistent
ith published estimates [48,49], we found decreasing termi-
al costs with age.
Pharmaceuticals (over the counter or prescription) were
ot included in our estimates because 2003 pre-dated Medi-
are Part D. The time span of the analysis does not cover im-
ortant treatment advances such as cisplatin-based adjuvant
hemotherapy [50] and pre-dated clear-cut evidence of sur-
ival benefits fromchemotherapy in late-stageNSCLC [51] and
he introduction of targeted therapies such as angiogenesis
52], epidermal growth factor receptor inhibitors [53,54], and
ther newanticancer agents [55,56].More patients today likely meceive chemotherapy or targeted therapies, which have costs
hat could dwarf those used in the time period of this study
57–60]. The impact of Medicare Part D on the relative trends of
atient liability and total cost of cancer care remain unknown
nd need to be evaluated. If the trends we observed (i.e., patient
iability increasing faster than total costs) continued, scientific
dvancements in lung cancer care may represent clinical ad-
ancements only for those with generous supplemental insur-
nce. SEER-Medicaredata for casesdiagnosed in2007will first be
ade available in 2011. Shortening the time frame required to
ollect, generate, disseminate and analyze the data, plus greater
etail about cumulative patient liability and out-of-pocket costs,
ould improve our ability to gauge the impacts of costs on
ealth decisions and health outcomes.
Patient and caregiver time costs and transportation costs
o undergo treatment were not available here, but should be
ncluded in a cost-effectiveness analysis conducted from the
ocietal perspective. Cancer therapies are increasingly deliv-
red in the outpatient setting, shifting substantial costs to
aregivers [13,61,62]. Despite excluding the 3 months prior to
iagnosis, patients in the sample had undiagnosed cancer and
ould have been receiving treatment related to disease symp-
oms [63].We defined a 30-day staging phase to isolate staging
osts from treatment costs, but this may have improperly cat-
gorized some staging costs as initial phase costs or some
nitial treatment costs as staging costs. Staging costs were not
stimated for patients undergoing resection, but the wide
ariation in staging practices [41,64] suggests that a micro-
osting approach based on procedure codes would be prefer-
ble in cost-effectiveness analyses to permit distinction be-
ween patient management algorithms.
Other limitations of the analysis include those common to
nalyses of SEER-Medicare data [14], such as omission of pa-
ients less than 65 years old, patients enrolled inHMOs, and an
nability to identify individuals, such as veterans, for whom
edicaremay have incomplete claims data.We did not inves-
igate how these patients’ costs differ from those patients
ith traditional Medicare. Medicare data are observational
nd are not collected specifically for health services research,
nd SEER areas are not entirely representative of the United
tates [14]. Our regression analyses were intended to compare
ime trends in cost components (vs. explaining variability in
osts) so they did not contain clinical covariates other than
ge and yielded very small R2 values. The total reimbursement
mounts are determined by CMS and providers are required
y law (with limited exceptions) to collect the full amount [65],
lthough SEER-Medicare files do not contain variables that
onfirm payment.
The costs of lung cancer care are substantial andMedicare is
aying a smaller proportion of the total cost over time. Our anal-
sis concurs with findings from other studies showing that
edicare beneficiaries are responsible for paying an ever-larger
hare of the costs [4]. Awareness of trends in cost sharing is
mportant topreventworseningof sociodemographicdisparities
n access and quality of care, yet the cost analysis literature con-
ains major gaps [66]. Finally, our analysis addressed common
imitations of published cost analyses, such as omission of vali-
ation studies or technical appendices with sufficient detail to
ake methods transparent and reproducible.
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